Special Issue "Antibody Drug Conjugates: Unlocking the Future of Immunotherapies"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 11733
Interests: targetted therapies; antibody drug conjugates; oncology; female infertily; functional genomics; 3D patient-derived multicellular models; exosomes; tumor microenvironment; drug development characterisation platforms
Antibody Drug Conjugates (ADC) are quintessential example of advanced biopharmaceutical therapies. These targeted nanomedicines use the specificity of monoclonal antibodies to guide highly potent cytotoxic payloads to specific target cell. The resulting ADCs have a broader therapeutic window than their potent payloads while sparing healthy cells. Currently there are 12 ADCs approved for the treatment of haematological and solid tumour malignancies including: ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin (Mylotarg™) , Moxetumomab pasudotox (Lumoxiti™), polatuzumab vedotin-piiq (Polivy™), Enfortumab vedotin (Padcev™), Sacituzumab govitecan (Trodelvy), Trastuzumab deruxtecan (Enhertu™), belantamab mafodotin-blmf (Blenrep™) , loncastuximab tesirine-lpyl (ZYNLONTA™), and totoaba vedotin-tftv (Tivdak). The field of ADC development is further growing in strength with more than 100 ADCs currently being investigated at either preclinical phase or at clinical trials.
Despite growing interest in this complex biopharmaceutical modality challenges remain to improve ADC quality, safety, and efficacy.
This Special Issue of Pharmaceutics will focus on recent advances in ADC development from ADC design including identification of new targets, antibody selection, development of new conjugation and linker chemistry technologies, novel payloads and mechanism of action, ADC characterisation platforms, to ADC preclinical characterisation including pharmacokinetics, pharmacodynamics, biodistribution, toxicity and efficacy studies and clinical studies looking at oncology and non-oncology applications. In addition, studies looking at development of small molecular conjugates and bispecifics and the use of artificial intelligence (AI) to drive the development of ADC technologies are encouraged. Review articles should be focused in addressing limitations in the field and discussing successful and discontinued ADCs as lessons learned.
Prof. Dr. Deyarina Gonzalez
Prof. Dr. R. Steven Conlan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antibody drug conjugates
- target antigens
- conjugation technologies
- artificial intelligence
- ADC payloads
- clinical trials
- preclinical development